References
- 1. Allen CE, Ladisch S, McClain KL. How I treat Langer-hans cell histiocytosis. Blood. 2015;126(1):26-35.
- 2. Lau SK, Chu PG, Weiss LM. lmmunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol. 2008;32(4):615-9.
- 3. Hutter C, Minkov M. Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies. Immunotargets Ther. 2016;5:81-91.
- 4. Tran G, Huynh TN, Paller AS. Langerhans cell histiocytosis: a neoplastic disorder driven by Ras-ERK pathway mutations. J Am Acad Dermatol. 2018;78(3):579-90.
- 5. Favara BE, Jaffe R. The histopathology of Langerhans cell histiocytosis. Br J Cancer Suppl. 1994;23:S17-23.
- 6. Steen AE, Steen KH, Bauer R, Bieber T. Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol. 2001;145 (1):137-40.
- 7. Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006-14.
- 8. Minkov M. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy. Expert Opin Pharmacother. 2018;19(3):233-42.
- 9. Gadner H, Grois N, Pötschger U, Minkov M, Aricò M, Braier J, et al. Improved outcome in multisystem Lang-erhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111(5):2556-62.
- 10. Behera B, Malathi M, Prabhakaran N, Divya K, Thappa DM, Srinivas BH. Dermoscopy of Langerhans cell histiocytosis. J Am Acad Dermatol. 2017;76(2S1):S79-81.
- 11. Kanik-Yuksek S, Ozkaya-Parlakay A, Gulhan B, Ozyoruk D, Karakus E, Cinel G, et al. A rare diagnosis in children: isolated pulmonary Langerhans cell histiocytosis. Clin Respir J. 2018;12(1):355-6.
- 12. Ladisch S. Treating Langerhans cell histiocytosis, globally. Pediatr Blood Cancer. 2018;65(8):e27079.
- 13. James WD, Berger TG, Elston DM, Neuhaus I. Andrews’ diseases of the skin: clinical dermatology. 12th ed. Edinburgh: Elsevier; 2016. p. 722-5.
- 14. Fitzpatrick TB, Goldsmith LA, Wolff K. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill. 2012. p. 1782-95.
- 15. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34(10):1514-21.
- 16. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421-33.
- 17. Pinkus GS, Lones MA, Matsumura F, Yamashiro S, Said JW, Pinkus JL. Langerhans cell histiocytosis: immunohistochemical expression of fascin, a dendritic cell marker. Am J Clin Pathol. 2002;118(3):335-43.
- 18. Ravi S. Treatment of adult onset multifocal single system Langerhans cell histiocytosis using single agent induction chemotherapy followed by maintenance oral etoposide and external beam radiotherapy. Int J Sci Res (Ahmedabad). 2016;5(6):74-6.
- 19. Felix CA, Blatt J. Etoposide and Langerhans cell histiocytosis: second malignancies, a second look. Pediatr Hematol Oncol. 1999;16(3):183-5.
- 20. Bolognia J, Jorizzo JL, Schaffer JV. Dermatology. 4th ed. Philadelphia: Elsevier Saunders; 2018. p. 1614-20.
- 21. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem Langerhans cell histiocytosis. J Pediatr. 2001;138(5):728-34.
- 22. Ng Wing Tin S, Martin-Duverneuil N, Idbaih A, Garel C, Ribeiro M, Parker JL, et al. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. Orphanet J Rare Dis. 2011;6:83.
- 23. Schmitt AR, Wetter DA, Camilleri MJ, Khan SP, Tollefson MM. Langerhans cell histiocytosis presenting as a blueberry muffin rash. Lancet. 2017;390(10090):155.